A possible role for HLA-DRB1*04:06 in statin-related myopathy in Japanese patients

Sai, Kimie; Kajinami, Kouji; Akao, Hironobu; Iwadare, Mizuho; Sato-Ishida, Ryoko; Kawai, Yasuyuki; Takeda, Kenji; Tanimoto, Takashi; Yamano, Takashi; Ishida, Tatsuro; Hirata, Ken‐ichi; Saku, Keijiro; Yagi, Shusuke; Soeki, Takeshi; Sata, Masataka; Ueno, Masashi; Miyazaki, Shunichi; Shiraki, Aya; Oyama, Jun‐ichi; Node, Koichi; Sugamura, Koichi; Ogawa, Hisao; Kurose, Kouichi; Maekawa, Keiko; Matsuzawa, Yusuke; Imatoh, Takuya; Hasegawa, Ryuichi; Saito, Yoshiro

doi:10.1016/j.dmpk.2016.09.002

Cited by 20 publications

(32 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[13][14][15] The last two population-based case-control articles in Czech and Japanese population showed no association between SLCO1B1 gene polymorphism and risk of myalgia/myopathy in these two specific population. [16,17] APOE gene APOE gene is the gene encodes Apolipoprotein E. Apo E is a basic element of triglyceride-rich lipoprotein chylomicrons and VLDL and a subclass of high-density lipoprotein cholesterol (HDL-C). ApoE had been frequently studied in relation to LDL-lowering response with statin users.…”

Section: Slco1b1 Genementioning

confidence: 99%

“…[25] Also, possible association of HLA-DRB1 carriers with SIM through an immune-mediated necrotising mechanism by the production of an autoantibody against HMGCR, a target molecule of statin, was determined, and the association of HLA-DRB1*11:01 with antibody-positive myopathy was shown in different populations. [17] RYR2 gene…”

Section: Hla-dr and Lilrb5 Genesmentioning

confidence: 99%

“…Hub a cek et al (2015) [16] Case-control There is no association between SLCO1B1 gene polymorphism and risk of myalgia/myopathy. Sai et al (2016) [17] Case-control HLA-DRB1*04:06 might be associated with SRM onset in a Japanese population. And No significant association of RYR2, SLCO1B1, and GATM variants with SRM were observed in same population.…”

Section: Article Title Study Design Conclusionmentioning

confidence: 99%

“…[27] Another article denies a significant association in a small Japanese population. [17] There were no enough data with high-quality evidence support the association of RYR2 gene polymorphism with SIM.…”

Section: Article Title Study Design Conclusionmentioning

confidence: 99%

“…[30] Also, there was no significant association of GATM polymorphism with SIM in Japanese population. [17] Angiotensin-converting enzyme and hepatic lipase genes…”

Section: Coq2 Genementioning

confidence: 99%

See 4 more Smart Citations

Clinical evidence of pharmacogenetics of statins: systematic literature review

Aldawsari

Shawaqfeh

2019

J Pharm Health Serv Res

View full text Add to dashboard Cite

Objectives A systematic review was conducted to explore the clinical evidence of pharmacogenetic testing with statins in a personalised approach to minimise the incidence of adverse drug reaction (ADR), ensure better response and optimise medication adherence. Methods Systematic literature review using PubMed and EMBASE/Medline database that includes all clinically relevant pharmacogenomic studies involving statins. Key findings Twenty-four articles were evaluated for a total of 120 articles screened. The included studies were classified according to study design (two randomised controlled trial studies (RCTs), three meta-analysis studies, two interventional studies, four prospective studies, 10 case-control studies, two cross-sectional studies and one data analysis study). There were 23 different genetic polymorphisms related to statins were studied clinically with the specified outcome either LDL-lowering response or adverse drug reaction. Those genes were diverse and involve metabolic enzymes, transporters and other receptors. Conclusions Many studies suggest a strong association between clinical outcomes and certain genes relevant to statins. However, these studies were observational and only a few were randomised controlled trials (RCTs). The strength of evidence to support pharmacogenetic testing for statin is not adequate.

show abstract

Section: Slco1b1 Genementioning

confidence: 99%

Section: Hla-dr and Lilrb5 Genesmentioning

confidence: 99%

Section: Article Title Study Design Conclusionmentioning

confidence: 99%

Section: Article Title Study Design Conclusionmentioning

confidence: 99%

“…[30] Also, there was no significant association of GATM polymorphism with SIM in Japanese population. [17] Angiotensin-converting enzyme and hepatic lipase genes…”

Section: Coq2 Genementioning

confidence: 99%

See 3 more Smart Citations

Clinical evidence of pharmacogenetics of statins: systematic literature review

Aldawsari

Shawaqfeh

2019

J Pharm Health Serv Res

View full text Add to dashboard Cite

show abstract

Polymorphisms of Drug Transporters and Clinical Relevance

Stage¹,

Kroetz²

2022

Drug Transporters

View full text Add to dashboard Cite

The association of GATM polymorphism with statin-induced myopathy: a systematic review and meta-analysis

Liu

Fan

Zhang

et al. 2020

Eur J Clin Pharmacol

View full text Add to dashboard Cite

Purpose Statin-induced myopathy (SIM) is the commonest reason for discontinuation of statin therapy. The aim of this present meta-analysis is to assess the relationship between glycine amidinotransferase gene (GATM) polymorphism and risk of SIM. Methods MEDLINE, EMBASE, Web of Science, and Cochrane Library databases were searched systematically for case-control studies investigating the relationship between GATM polymorphism and SIM. Retrieved articles were carefully reviewed and assessed according to the inclusion criteria. Associations were assessed in pooled data by calculating odds ratio with 95% confidence intervals. Subgroup analysis was performed according to comedications and severity of SIM. Results Six studies with 707 cases and 2321 controls were included in this meta-analysis. GATM rs9806699 G>A was associated with decreased risk of SIM (OR = 0.80, 95% CI 0.68–0.94, P = 0.006). This association remained significant in the subgroup with fibrates or niacin excluded. However, the association of rs9806699 G>A with severe SIM was not significant. In addition, another two variations at GATM, rs1719247 C>T, and rs1346268 T>C were also associated with declined risk of SIM. Conclusions GATM polymorphism including rs9806699 G>A, rs1719247 C>T, and rs1346268 T>C may be protective factors of SIM. GATM rs9806699 G>A may only exert protective effect on mild SIM cases. Our meta-analysis indicates that GATM polymorphism may represent a pharmacogenomics biomarker for predicting incidence of SIM, which contributes to risk stratification and optimizing statin adherence.

show abstract

A possible role for HLA-DRB1*04:06 in statin-related myopathy in Japanese patients

Cited by 20 publications

References 18 publications

Clinical evidence of pharmacogenetics of statins: systematic literature review

Clinical evidence of pharmacogenetics of statins: systematic literature review

Polymorphisms of Drug Transporters and Clinical Relevance

The association of GATM polymorphism with statin-induced myopathy: a systematic review and meta-analysis

Contact Info

Product

Resources

About